Teratogenicity of sodium valproate

Area of Science:

• Pharmacology
• Teratology
• Obstetrics

Background:

• Sodium valproate (VPA), a widely used antiepileptic drug (AED) and mood stabilizer, has demonstrated teratogenic potential in previous studies.
• Existing research on VPA teratogenicity is often limited by small sample sizes and retrospective designs.
• Factors influencing VPA teratogenicity include polytherapy, dosage, maternal/infant metabolism, gestational exposure age, and genetic susceptibility.

Purpose of the Study:

• To consolidate evidence on the teratogenic effects of sodium valproate (VPA).
• To highlight the association between VPA and various major/minor malformations in offspring.
• To underscore the need for improved research methodologies and pregnancy registries for AEDs.

Main Methods:

• Review of existing literature on sodium valproate (VPA) teratogenicity.
• Analysis of factors contributing to VPA-induced birth defects.
• Examination of the relationship between VPA dosage, polytherapy, and adverse fetal outcomes.

Main Results:

• VPA is associated with a 20-fold increase in neural tube defects.
• Other VPA-related malformations include orofacial clefts, cardiovascular and genitourinary defects, limb abnormalities, developmental delay, endocrinological disorders, and autism.
• Higher VPA doses and polytherapy increase the risk of adverse outcomes.

Conclusions:

• Sodium valproate (VPA) poses significant teratogenic risks, necessitating careful consideration during pregnancy.
• Increased VPA dosage and combination therapy exacerbate the risk of congenital malformations.
• The establishment of national and international pregnancy registries is crucial for better understanding and mitigating AED-related risks.